Why is the Imugene (ASX:IMU) share price lifting 7% today?

Another day in the green for Imugene.

| More on:
A young woman wearing glasses and a red top looks at her laptop smiling

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in the immunotherapy company Imugene Limited (ASX: IMU) are 7.8% higher in afternoon trade and are now changing hands at 44 cents each.

The Imugene share price is gaining ground today despite there being no market-sensitive news from the company.

However, Imugene shares have risen 54% from their previous low on 20 August. So, it appears there is momentum behind the biotech's share price when scoping out a wider timeframe.

Imugene also released an investor presentation on Tuesday that is worthwhile covering. Here are the details.

What did Imugene announce in its investor presentation?

In the presentation, Imugene detailed several investment highlights regarding its novel technology and treatment platforms.

These include the company's HER-Vaxx Phase 2 trial in gastric cancer and PD1-Vaxx trials in its "B-Cell activating immunotherapies" platform, both of which have gained traction of late.

The company also has early-stage trials underway with its 'Oncolytic virotherapies' and 'OnCARlytics in cellular therapy' platforms.

They also discussed the progress and timeline of each, outlining each stage of the pipeline. Imugene has intellectual property protection over each of its 5 treatment segments until 2036, at least.

Imugene also included information on the value that the Vaxina Pty Ltd acquisition provides with its CF33 oncology technology.

Whilst the presentation was relatively brief, it did encapsulate Imugene's recent clinical trial momentum and its progress in other business segments.

For instance, the company recently announced positive readouts from its Phase 2 HER-Vaxx clinical trial and was granted patent protection in Japan.

The Imugene share price quickly rallied 13% from 45.5 cents to a new 52-week high of 51.5 cents in the days following the patent announcement on 22 September.

From this point, Imugene shares began the march back down.

Imugene shares have moved directly in line with the S&P/ASX 200 Pharmaceuticals & Biotechnology index (ASX: AXPBKD), which has slumped 8.6% in this time.

The broader S&P/ASX 200 Health Care index (ASX: XHJ) has also dropped 7.8% over the same period, indicating weakness in the wider ASX biotechnology and health care sectors.

Imugene share price snapshot

The Imugene share price has exploded 340% higher this year to date, doubling its return over the past 12 months to 685%.

These results far outpace the S&P/ASX 200 index (ASX: XJO) which has returned about 20% this past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing hump day session for the ASX today.

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX managed to bank a small rise this Tuesday.

Read more »

Sport trainer talking to little girl who is climbing wooden ladder in gym.
Share Gainers

Why Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today

These shares are gaining on Tuesday, but why?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Financial Shares

5 best ASX 200 financial shares of FY25 (CBA didn't make the cut!)

These stocks were well and truly 'in the black' for share price growth last financial year.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Share Gainers

Why Amaero, Black Cat, Domino's, and Ramelius shares are racing higher today

These shares are having a good session on Tuesday. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough start to the trading week for investors this Monday.

Read more »

two computer geeks sit across from each other with their laptop computers touching as they look confused and confounded by what they are seeing on their screens.
Share Gainers

ASX tech shares outperformed US tech stocks by 2:1 in FY25. Here's why

Forget the Magnificent 7! Aussie tech shares had twice as much price growth as US tech stocks in FY25.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Share Gainers

Why Bellevue Gold, Cobram, Hub24, and Nanosonics shares are pushing higher

These shares are starting the week on a positive note. But why?

Read more »